Search Results for: TERT

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel IRS1 insulin receptor substrate 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Activated NTRK3 signals through PI3K
  • Growth hormone receptor signaling
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
Novel EXOC3 exocyst complex component 3
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Insulin processing
  • VxPx cargo-targeting to cilium
Novel IFT57 intraflagellar transport 57
  • Hedgehog 'off' state
  • Intraflagellar transport
  • Intraflagellar transport
Novel ICE1 interactor of little elongation complex ELL subunit 1
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
Novel NDUFS6 NADH:ubiquinone oxidoreductase subunit S6
  • Respiratory electron transport
  • Complex I biogenesis
  • NADH
  • Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
Novel HMGB2 high mobility group box 2
  • Apoptosis induced DNA fragmentation
Novel ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2
  • Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
Novel PDCD6 programmed cell death 6
  • Calcium
  • Zinc
  • Calcium citrate
  • Calcium Phosphate
  • Calcium phosphate dihydrate
  • Zinc acetate
Novel PTMA prothymosin alpha
HSP90AA1 heat shock protein 90 alpha family class A member 1
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • RHOBTB2 GTPase cycle
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Potential therapeutics for SARS
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • CCT-018159
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Polaprezinc
  • Alvespimycin
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • CTLA4 inhibitory signaling
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib
TUBA1B tubulin alpha 1b
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane
  • Gap junction assembly
  • MHC class II antigen presentation
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Recruitment of NuMA to mitotic centrosomes
  • Formation of tubulin folding intermediates by CCT/TriC
  • Post-chaperonin tubulin folding pathway
  • Recycling pathway of L1
  • Recycling pathway of L1
  • Hedgehog 'off' state
  • Cilium Assembly
  • Intraflagellar transport
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate Formins
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
  • COPI-independent Golgi-to-ER retrograde traffic
  • Mitotic Prometaphase
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Carboxyterminal post-translational modifications of tubulin
  • Carboxyterminal post-translational modifications of tubulin
  • HCMV Early Events
  • Assembly and cell surface presentation of NMDA receptors
  • Activation of AMPK downstream of NMDARs
  • Aggrephagy
  • Aggrephagy
  • EML4 and NUDC in mitotic spindle formation
  • Sealing of the nuclear envelope (NE) by ESCRT-III
  • Kinesins
  • Epothilone D
  • Patupilone
  • CYT997
  • 2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE
DYNLL1 dynein light chain LC8-type 1
  • Activation of BIM and translocation to mitochondria
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Macroautophagy
  • MHC class II antigen presentation
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • Intraflagellar transport
  • RHO GTPases Activate Formins
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • COPI-independent Golgi-to-ER retrograde traffic
  • Mitotic Prometaphase
  • AURKA Activation by TPX2
  • HCMV Early Events
  • Aggrephagy
  • Aggrephagy
  • EML4 and NUDC in mitotic spindle formation
RELA RELA proto-oncogene, NF-kB subunit
  • Activation of NF-kappaB in B cells
  • RIP-mediated NFkB activation via ZBP1
  • Regulated proteolysis of p75NTR
  • Downstream TCR signaling
  • NF-kB is activated and signals survival
  • Senescence-Associated Secretory Phenotype (SASP)
  • FCERI mediated NF-kB activation
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • PKMTs methylate histone lysines
  • Transcriptional regulation of white adipocyte differentiation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Interleukin-1 processing
  • SUMOylation of immune response proteins
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • CD209 (DC-SIGN) signaling
  • CLEC7A/inflammasome pathway
  • The NLRP3 inflammasome
  • Transcriptional Regulation by VENTX
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • Purinergic signaling in leishmaniasis infection
  • Dimethyl fumarate
  • SC-236
PRKCA protein kinase C alpha
  • Calmodulin induced events
  • Disinhibition of SNARE formation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • EGFR Transactivation by Gastrin
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Syndecan interactions
  • Acetylcholine regulates insulin secretion
  • Ca2+ pathway
  • Trafficking of GluR2-containing AMPA receptors
  • G alpha (z) signalling events
  • Depolymerisation of the Nuclear Lamina
  • HuR (ELAVL1) binds and stabilizes mRNA
  • WNT5A-dependent internalization of FZD4
  • VEGFR2 mediated cell proliferation
  • RHO GTPases Activate NADPH Oxidases
  • Response to elevated platelet cytosolic Ca2+
  • RET signaling
  • ROBO receptors bind AKAP5
  • ROBO receptors bind AKAP5
  • Phosphatidyl serine
  • Vitamin E
  • Tamoxifen
  • Ingenol mebutate
  • Aprinocarsen
  • Midostaurin
  • Perifosine
  • Ellagic acid
  • Bryostatin 1
  • alpha-Tocopherol succinate
  • D-alpha-Tocopherol acetate
CDKN2A cyclin dependent kinase inhibitor 2A
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Transcriptional Regulation by VENTX
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Apoptotic factor-mediated response
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • Regulation of TP53 Degradation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function
  • Evasion of Oncogene Induced Senescence Due to p14ARF Defects
  • Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects
  • Bladder cancer
  • Type II diabetes mellitus
  • Pancreatic cancer
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Chronic myeloid leukemia (CML)
  • Oral cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Glioma
  • Osteosarcoma
  • Squamous cell carcinoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Malignant islet cell carcinoma
  • Laryngeal cancer
  • Hepatocellular carcinoma
  • Esophageal cancer
  • Malignant melanoma
CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Glioma
  • Malignant melanoma
  • Cervical cancer
FOXO3 forkhead box O3
  • Signaling by NODAL
  • AKT phosphorylates targets in the nucleus
  • Constitutive Signaling by AKT1 E17K in Cancer
  • MAPK6/MAPK4 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Regulation of FOXO transcriptional activity by acetylation
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
MET MET proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D mediated inhibition of cell attachment and migration
  • RAF/MAP kinase cascade
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • MECP2 regulates neuronal receptors and channels
  • K-252a
  • SGX-523
  • 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
  • N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
  • 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
  • N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
  • 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  • AMG-208
  • 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
  • Crizotinib
  • Cabozantinib
  • Capmatinib
  • Fostamatinib
  • Tivantinib
  • Brigatinib
  • Amuvatinib
  • Renal cell carcinoma
  • Cholangiocarcinoma
  • Gastric cancer

Page 1 out of 5 pages